Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake

European Journal of Pharmacology

Volumn 370, Issue 2, 1999, Pages 125-131

  Budygin, Evgeny A ^a   Gainetdinov, Raul R ^b,c   Kilpatrick, Michaux R ^a   Rayevsky, Kirill S ^c   Männistö, Pekka T ^d   Wightman, R Mark ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Dopamine release; Dopamine synthesis; Dopamine uptake; GBR 12909; Microdialysis; Tolcapone; Voltammetry, cyclic

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; TOLCAPONE; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; POTENTIOMETRY; PRIORITY JOURNAL; RAT;

ANIMALS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CORPUS STRIATUM; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; ELECTRIC STIMULATION; ENZYME INHIBITORS; INJECTIONS, INTRAPERITONEAL; MALE; MICRODIALYSIS; NITROPHENOLS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; SYNAPTIC TRANSMISSION;

EID: 0033004237     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00084-9     Document Type: Article

References (31)

1. Baur J.E., Kristensen E.W., May L.J., Wiedemann D.J., Wightman R.M. Fast-scan voltammetry of biogenic amines. Anal. Chem. 60:1988;1268-1272.
2. Budygin E.A., Gainetdinov R.R., Rayevsky K.S., Li I.H., Männistö P.T. Microdialysis study of tolcapone effect during blockade of neuronal dopamine re-uptake caused by GBR 12909. Eksp. Klin. Farmakol. 60:1997;8-10. in Russian.
3. Budygin E.A., Gainetdinov R.R., Männistö P.T., Rayevsky K.S. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal extracellular dopamine level in rats under the blockade of dopamine uptake. Soc. Neurosci. Abstr. 23:1997;400.
4. Budygin E.A., Gainetdinov R.R., Männistö P.T., Rayevsky K.S. Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa. Biull. Eksp. Biol. Med. 125:1998;168-171. in Russian.
5. Carlsson A., Davis J.N., Kehr W., Lindqvist M., Atack C.V. Simultaneous measurements of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg's Arch. Pharmacol. 275:1972;153.
6. Da Prada M., Zürcher G., Kettler R., Colzi A. New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and COMT by Ro 40-7592. Adv. Behav. Biol. 39:1991;723-732.
7. Gainetdinov R.R., Sotnikova T.D., Grekhova T.V., Rayevsky K.S. Effects of a psychostimulant drug, Sydnocarb, on rat brain dopaminergic transmission in vivo. Eur. J. Pharmacol. 340:1997;53-58.
8. Garris P.A., Walker Q.D., Wightman R.M. Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res. 753:1997;225-234.
9. Gottwald M.D., Bainbridge J.L., Dowling G.A., Amonoff M.J., Alldredge B.K. New pharmacotherapy for Parkinson's disease. Ann. Pharmacother. 31:1997;1205-1217.
10. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. USA. 95:1998;4029-4034.
11. Kaakkola S., Wurtman R.J. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res. 587:1992;241-249.
12. Kaakkola S., Gordin A., Männistö P.T. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen. Pharmacol. 25:1994;813-824.
13. Kawagoe K.T., Garris P.A., Wiedemann D.J., Wightman R.M. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience. 51(1):1992;55-64.
14. Kawagoe K.T., Zimmerman J.B., Wightman R.M. Principles of voltammetry and microelectrode surface states. J. Neurosci. Methods. 48:1993;225-240.
15. Limousin P., Pollak P., Pfefen J.P., Tournier-Gervason C.L., Dubuis R., Perret J.E. Acute administration of levodopa-benzerazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin. Neuropharmacol. 18:1995;258-265.
16. Maj L.J., Kuhr W.G., Wightman R.M. Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fast-scan in vivo voltammetry. J. Neurochem. 51:1988;1060-1069.
17. Maj J., Rogoz Z., Skuza G., Sowinska H., Superata J. Behavioral and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J. Neural Transm. Parkinson's Dis. Dementia Sect. 2:1990;101-112.
18. Männistö P.T., Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. 66:1990;317-323.
19. Männistö P.T., Tuomainen P., Tuominen R.K. Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br. J. Pharmacol. 105:1992;569-574.
20. 2 receptor-mediated function: behavioral indices.
21. Napolitano A., Zürcher G., Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats. Eur. J. Pharmacol. 273:1995;215-221.
22. Near J.A., Bigelow J.C., Wightman R.M. Comparison of uptake of dopamine in rat striatal chopped tissue and synaptosomes. J. Pharmacol. Exp. Ther. 245:1988;921-927.
23. Nissbrandt H., Engberg G., Pileblad E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra. Naunyn-Schmiedeberg's Arch. Pharmacol. 344:1991;16-28.
24. Paxinos, G., Watson, C. 1986. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
25. Sedek G., Jorga K., Schmitt M., Burns R.S., Leese P. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol. 20:1997;531-541.
26. Waters C.H., Kurth M., Bailey P., Shulman L.M., LeWitt P., Dorflinger E., Deptula D., Pedder S. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology. 49:1997;665-671.
27. Westerink B.H.C., Damsma G., De Vries J.B., Koning H. Dopamine re-uptake inhibitors show inconsistent effects on in vivo release of dopamine as measured by intracerebral dialysis in the rat. Eur. J. Pharmacol. 135:1987;123-128.
28. Wightman R.M., Zimmerman J.B. Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res. 15:1990;135-144.
29. Zürcher G., Colzi A., Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J. Neural. Transm. 32:1990;375-380. Suppl.
30. Zürcher G., Keller H.H., Kettler R., Borgulya J., Bonetti E.P., Eigenmann R., Da Prada M. Ro 40-7592, a novel, very potent and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv. Neurol. 53:1990;497-503.
31. Zürcher G., Dingemanse J., Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv. Neurol. 60:1993;641-647.